FDA clears atezolizumab combo for Stage III dMMR colon cancer
The agency's approval covers adjuvant use of the immunotherapy alongside chemotherapy in patients as young as two.
The FDA approved atezolizumab, sold as Tecentriq by Genentech, Inc., on October 8, 20261 for use as an adjuvant therapy in a specific colon cancer population.
The approval applies to patients two years of age and older whose Stage III colon cancer is mismatch repair deficient, or dMMR1. Under the new approval, atezolizumab is given alongside a chemotherapy regimen that pairs a fluoropyrimidine with oxaliplatin, rather than as a standalone treatment.
This marks an expansion of atezolizumab's approved uses to include pediatric patients in this adjuvant colon cancer setting, broadening the drug's label beyond adult-only indications it has carried in other cancer types. The FDA's notice does not include additional detail on trial data, dosing schedule, or further regulatory milestones beyond confirming the approval date and the qualifying patient population.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.